Prospective randomized controlled study for preventive effect of menatetrenone against the recurrence of hepatocellular carcinoma after hepatectomy

Prospective randomized controlled study for preventive effect of menatetrenone against the recurrence of hepatocellular carcinoma after hepatectomy - Preventive effect of menatetrenone against recurrence of hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001815

Enrollment

Registered

2009-03-30

Start date

2005-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

The study was designed to test the hypothesis that MNT would reduce the incidence of recurrence of HCC in patients underwent initial hepatectomy. The patients stated to take 15 mg of menatetrenone, 3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergo curative hepatectomy at the Second Department of Surgery, Dokkyo Medical University.

Exclusion criteria

Exclusion criteria: Patients who take warfarin or other vitamin K analogs.

Design outcomes

Primary

Measure	Time frame
Disease-free survival period after hepatectomy	—

Countries

Japan

Contacts

Public ContactTokihiko Sawada

Dokkyo Medical University Second Department of Surgery

tsawada@dokkyomed.ac.jp0282-86-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026